Vis enkel innførsel

dc.contributor.authorOdsæter, Ingrid Hov
dc.contributor.authorÅsberg, Arne
dc.contributor.authorVanky, Eszter
dc.contributor.authorMørkved, Siv
dc.contributor.authorStafne, Signe Nilssen
dc.contributor.authorSalvesen, Kjell Å
dc.contributor.authorCarlsen, Sven Magnus
dc.date.accessioned2020-04-28T13:44:59Z
dc.date.available2020-04-28T13:44:59Z
dc.date.created2016-08-24T18:55:27Z
dc.date.issued2016
dc.identifier.citationDiabetology and Metabolic Syndrome. 2016, 8 (43), .en_US
dc.identifier.issn1758-5996
dc.identifier.urihttps://hdl.handle.net/11250/2652802
dc.description.abstractBackground Gestational diabetes mellitus (GDM) increases the risk for preeclampsia and macrosomia. GDM is conventionally diagnosed by an oral glucose tolerance test (OGTT). Hemoglobin A1c (HbA1c) is a marker for the average glucose level the last 2–3 months. We aimed to study if HbA1c alone or in combination with patient characteristics can be used to screen for GDM and reduce the number of OGTTs, and whether it could predict preeclampsia or birth weight. Methods 855 women from a previous study on the effect of exercise on GDM prevalence were eligible, whereof 677 were included. GDM was diagnosed by WHO 1999 criteria (GDM-WHO) and modified IADPSG criteria (GDM-IADPSG), at pregnancy weeks 18–22 and 32–36. HbA1c analyzed at pregnancy weeks 18–22 and 32–36, variables from patient history and clinical examination were considered for logistic regression models. The diagnostic accuracy was assessed by ROC curve analysis. Results Accumulated GDM prevalence was 6.7 % by WHO and 7.2 % by modified IADPSG criteria. Nearly a third could potentially have avoided an OGTT by using HbA1c to exclude GDM-IADPSG with a sensitivity of 88 % at week 18–22 and 97 % at week 32–36. Further, 16 % could have avoided an OGTT with a sensitivity of 96 % using HbA1c at week 18–22 to exclude GDM-IADPSG throughout pregnancy. HbA1c was not accurate at diagnosing GDM-IADPSG, and it was inaccurate at screening for GDM-WHO at any time point. Adding other predictors did not increase the number of potentially avoidable OGTTs significantly. HbA1c was not significantly associated with preeclampsia or birth weight. Conclusions HbA1c could potentially reduce the number of OGTTs.en_US
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleHemoglobin A1c as screening for gestational diabetes mellitus in Nordic Caucasian womenen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber12en_US
dc.source.volume8en_US
dc.source.journalDiabetology and Metabolic Syndromeen_US
dc.source.issue43en_US
dc.identifier.doi10.1186/s13098-016-0168-y
dc.identifier.cristin1375295
dc.description.localcodeOpen Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal